ReviewArchives of pharmacal research2025
Biodegradable gelatin methacryloyl microneedles: a new paradigm in transdermal drug delivery.
Review in Archives of pharmacal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A core-shell microneedle platform for the spatiotemporal codelivery of dual-agent therapeutics precisely orchestrates diabetic wound healing.Journal of nanobiotechnology · 2026Article
- Hydrogel-Based Monitoring in Perioperative Anesthesia: A Conceptual Review and Translational Perspective.International journal of nanomedicine · 2026Review
- Rational Design and Responsive Transdermal Cargo Delivery of Microneedles in the Treatment of Melanoma.International journal of nanomedicine · 2026Review
- The construction of the gelatin methacrylate microneedle -encapsulated newcastle disease virus and its antitumor effect in hepatocellular carcinoma.Journal of biological engineering · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Microneedles (MN) have emerged as a promising transdermal drug delivery technology that offers advantages such as minimal invasiveness, high biocompatibility, and biodegradability. Gelatin methacryloyl (GelMA)-based MNs have gained attention because of their flexibility, mechanical strength, and modification capabilities, which support controlled drug release. The synthesis process of GelMA involves crosslinking using UV light, resulting in a stable hydrogel structure that supports therapeutic applications, such as wound healing, cancer therapy, and glucose monitoring. However, challenges such as skin penetration strength, drug-loading capacity, and regulatory standards still require solutions. Material and design innovations, particularly the combination of GelMA with nanomaterials and natural polymers, have the potential to enhance the MN efficiency and expand its applications in various medical fields. This review explores the latest developments in GelMA-based MN design and their future potential as reliable therapeutic devices.
Indexed as
Identifiers
40332454What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.